KyungDong Pharm home
Over-the-Counter Medicines

KyungDong Aspirin enteric coated Tab.

Product Category
Cardiovascular disease and blood clot prevention drugs
Active Ingredients
aspirin
Appearance
A white, enteric-coated tablet.
Reimbursement Code
648103320
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Aspirin (KP)----100mg
- Additives: powdered cellulose, acrylic white (93O18509), corn starch, pregelatinized starch, talc

2. Effectiveness
1) Inhibition of blood clot formation in the following diseases
· Myocardial infarction
· Cerebral infarction
· Unstable angina
2) Inhibition of thrombus formation after coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA)
3) Reduced cardiovascular risk in high-risk patients (patients with complex risk factors such as family history of ischemic heart disease, high blood pressure, hypercholesterolemia, obesity, diabetes, etc.)

3. Dosage and dosage
Adults, 1 tablet once a day,
Do not take high doses without a doctor's prescription.

Preparations containing aspirin are generally not administered on an empty stomach due to the adverse reaction of gastrointestinal bleeding. However, since this preparation is an enteric-coated tablet, it can be taken before meals with plenty of water.
Because there is a risk of bleeding, when undergoing surgery (including dental surgery), you must inform your doctor that you are taking aspirin and receive consultation.

4. Precautions for use
1. Warning
If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.

2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or other salicylic acid preparations
2) Peptic ulcer patients
3) Patients with aspirin asthma (induction of asthma attacks by non-steroidal anti-inflammatory drugs, etc.) or a history of it
4) Hemophilia patients
5) Patients with severe liver impairment
6) Patients with severe renal impairment
7) Patients with severe cardiac dysfunction
8) Patients with bleeding tendency
9) Patients who concurrently take methotrexate in doses of 15 milligrams (15 mg/week) or more for a week
10) Pregnant women in the third trimester of pregnancy (refer to section 7. Administration to pregnant and lactating women)

3. Administer with caution to the following patients.
1) Patients with renal impairment or cardiovascular circulatory dysfunction (neovascular disease, congestive heart failure, volume loss, major surgery, sepsis or major bleeding accident, etc.)
2) Patients with hepatic impairment or its history
3) Patients with cardiac dysfunction
4) Patients with blood abnormalities or history thereof
5) Patients with bronchial asthma
6) Patient before surgery
7) Infants under 3 years of age
8) Patients with a history of hypersensitivity to painkillers, anti-inflammatory drugs, antirheumatic drugs, or other allergic diseases
9) Elderly people
10) Patients taking concurrent anticoagulants (refer to section 6. Interactions)
11) Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This drug may induce hemolysis and hemolytic anemia. Factors that may increase the risk of hemolysis are high doses, fever, and acute infection.

4. Adverse reactions
The adverse drug reactions described were based on spontaneous post-marketing reports involving short-term and long-term oral administration of aspirin preparations.
1) Shock: Shock and anaphylactoid symptoms (difficulty breathing, flushing of the body, angioedema, urticaria, etc.) may occur, so observe thoroughly and if abnormalities are found, stop administration and take appropriate measures. This drug may cause an asthma attack.
2) Hypersensitivity: Hypersensitivity symptoms such as erythema, itchiness, nasal congestion, cardio-respiratory disorders, and sometimes rash, edema, hives, rhinitis, and conjunctivitis may occur. If these symptoms appear, discontinue administration.
3) Skin: In rare cases, Riel syndrome (toxic epidermal necrosis), drug reaction with increased eosinophils and systemic symptoms (DRESS syndrome), Stevens-Johnson syndrome (cutaneous mucous membrane ocular syndrome), and exfoliative dermatitis may occur, so observe thoroughly and if any abnormalities occur, discontinue administration and take appropriate measures.
4) Blood: In rare cases, aplastic anemia, anemia, decreased leukocyte count, decreased platelet count, decreased platelet function (delayed bleeding time), etc. may occur, so observe thoroughly and if any abnormality occurs, discontinue administration and take appropriate measures.
Hemolysis and hemolytic anemia have been reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
5) Digestive system: Symptoms such as loss of appetite, heartburn, stomach pain, nausea, and vomiting may appear, and long-term administration may cause adverse reactions to the gastrointestinal tract, especially gastrointestinal bleeding, peptic ulcer, and perforation.
6) Mental nervous system: Symptoms such as ringing in the ears, deafness, dizziness, headache, and excitement may occur. If these symptoms appear, reduce the dose or stop administration.
7) Liver: In rare cases, liver failure may occur. Very rarely, transient liver damage due to elevated liver transaminases has been reported.
8) Kidney: Renal impairment and acute renal failure have been reported.
9) Others: If hyperventilation, metabolic acidosis, etc. occur, reduce the dose or discontinue administration as blood concentration may increase significantly.

5. General precautions
1) The causal relationship between salicylic acid preparations and Reye's syndrome is not clear, but there are epidemiological investigation reports showing a relationship, so administer it carefully to patients under the age of 14 with chickenpox or influenza only in unavoidable cases, and sufficiently observe the patient's condition after administration.
(Ray's syndrome: Very rare in children, following viral diseases such as chicken pox or influenza, symptoms such as severe vomiting, impaired consciousness, convulsions (acute cerebral edema), fat deposition in organs other than the liver, mitochondrial deformation, rapid rise in GOT, GPT, LDH, and CPK, hyperammonemia, hypoprothrombinemia, and hypoglycemia occur in a short period of time, resulting in a high mortality rate.)
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment (treatment based on symptoms), not causative treatment.
3) When using for chronic diseases (chronic rheumatism, degenerative arthritis, etc.), consider the following.
(1) In case of long-term administration, conduct regular clinical tests (urinalysis, blood tests, liver function tests, etc.), and if any abnormalities are found, take appropriate measures such as reducing the dose or discontinuing administration.
(2) Treatments other than drug therapy are also considered.
4) When using for acute diseases, consider the following:
(1) Administer taking into account the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causal treatment, implement it.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Excessive temperature drop, collapse, and cooling of extremities may occur, so pay close attention to the patient's condition after administration, especially in children and elderly patients with high fever or patients with consumptive diseases.
6) Since infection can be hidden, when using for inflammation caused by infection, use an appropriate antibacterial agent and administer carefully while observing sufficiently.
7) For elderly people and children, administer with caution in the minimum necessary amount and pay particular attention to the occurrence of adverse reactions.
8) In cases where aspirin was administered within 1 week before surgery, a significant increase in blood loss was reported.
9) Overdosage of this drug may cause salicylic acid poisoning, and in severe cases, hallucinations, convulsions, coma, respiratory paralysis, and circulatory failure may cause death.
10) When using this drug for cardiovascular or other purposes, consult a doctor or pharmacist. If you self-treat for purposes other than the efficacy or effect, severe adverse reactions may occur.
11) Since this drug has an inhibitory effect on platelet coagulation for a certain period of time after taking it, bleeding tendency may continue during or after surgery (including simple surgeries such as dental surgery).
12) Salicylic acid preparations may increase the risk of bleeding due to their platelet inhibitory effect. Symptoms such as bleeding, hematoma, nosebleeds, genitourinary bleeding, and gum bleeding have been observed during surgery. Rarely or very rarely, gastrointestinal bleeding or cerebral hemorrhage (especially in cases of uncontrolled hypertension or when used in combination with other anti-hemostatic agents) may occur and may be life-threatening.
13) At low doses, aspirin reduces uric acid excretion, which may cause the development of gout in patients with a predisposition to gout.
14) Some non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, may weaken the effect of aspirin on inhibiting platelet aggregation. Therefore, if a patient taking aspirin wants to take nonsteroidal anti-inflammatory drugs (NSAIDs), they should consult their doctor.
15) Drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome): Drug reaction with increased eosinophils and systemic symptoms (DRESS syndrome) has been reported in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these cases were fatal or life-threatening. DRESS syndrome is usually, but not always, accompanied by fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, and myositis. Sometimes the symptoms of DRESS syndrome may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not mentioned here may be involved. It is important to note that early symptoms of hypersensitivity, such as fever or lymphadenopathy, may appear even if the rash is not evident. If these signs or symptoms occur, this drug should be discontinued immediately and the patient evaluated.

6. Interaction
1) Anticoagulants, thrombolytic agents/other platelet aggregation inhibitors, hemostatic agents, and anti-diabetic agents (insulin agents, tolbutamide, etc.): The effect of this drug may increase and the risk of bleeding may increase, so administer with caution, including reducing the dose.
2) Uric acid excretion stimulators (benzbromarone, probenecid): When administered together with this drug, the uric acid excretion effect is suppressed. It may reduce the action of thiazide diuretics.
3) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs (NSAIDs) and salicylic acid may delay the excretion of methotrexate from the renal tubules and increase the fatal hematological toxicity of methotrexate. Therefore, high doses of methotrexate (15 mg/week or more) should not be administered in combination with aspirin. If administered together, use low doses of methotrexate with caution. It must be administered.
4) Lithium preparations: There have been reports that lithium poisoning occurred due to increased blood concentration of lithium when administered in combination with this drug, so be sure to observe thoroughly and administer with caution during concurrent use.
5) Some non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen: When administered together with this drug, the irreversible inhibitory effect of platelet aggregation caused by aspirin may be reduced. The clinical relevance of this interaction is unknown. In patients at increased risk for cardiovascular disease, the cardiovascular protective effect of aspirin may be limited when administered concurrently with some non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen.
6) Other non-steroidal anti-inflammatory drugs (NSAIDs) and salicylic acid preparations: Do not administer in combination with this drug because bleeding may increase or renal function may decrease.
7) Ibuprofen: When administered in combination with this drug, the irreversible inhibitory effect of platelet aggregation caused by aspirin is reduced. The cardioprotective effect of aspirin may be limited when administered in combination with ibuprofen in patients at increased risk for cardiovascular disease.
8) Selective cytotonin reuptake inhibitors (SSRIs): Co-administration with this drug may increase the risk of upper gastrointestinal bleeding.
9) Digoxin: When administered in combination with this drug, renal excretion may be reduced and the plasma concentration of digoxin may increase.
10) Systemically acting corticosteroid preparations (except hydrocortisone for replacement therapy for Addison's disease): When administered together with this drug, the blood concentration of salicylic acid preparations decreases.
11) Angiotensin-converting enzyme inhibitor (ACE inhibotor): When this drug is administered in combination with high doses, the glomerular filtration rate decreases and the blood pressure lowering effect decreases due to the inhibition of vasodilatory prostaglandins.
12) Valproic acid: When administered in combination with this drug, the toxicity of valproic acid increases due to protein bond displacement.
13) Alcohol: When administered in combination with this drug, damage to the gastrointestinal mucosa increases and bleeding time is prolonged due to the synergistic effect of salicylic acid and alcohol.

7. Administration to pregnant and lactating women
1) Inhibition of prostaglandin synthesis may have adverse effects on pregnancy or fetal development. Epidemiological studies have raised concerns that the use of prostaglandin synthesis inhibitors in early pregnancy may increase the risk of miscarriage and organ defects. This risk is expected to increase depending on the administered dose and administration period. There is no valid data to prove the relationship between the risk of miscarriage and the use of salicylic acid medications. Although epidemiological studies on organ defects with salicylic acid are inconsistent, an increased risk for gastroschiasis cannot be ruled out. There was no increase in organ defects in 14,800 mother-child pairs administered this drug during early pregnancy (months 1 to 4).
Reproductive toxicity was shown in animal tests.
Salicylic acid-containing preparations should not be administered during the first and second trimesters of pregnancy unless absolutely necessary. When administering salicylic acid-containing preparations to women trying to become pregnant or in the first and second trimesters of pregnancy, the dose should be maintained at a low level and taken for the minimum period of time possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can cause fetal cardiopulmonary toxicity (premature closure of the ductus arteriosus and pulmonary hypertension) and decreased renal function (oligohydroamnisis). Additionally, in the final trimester of pregnancy, they prolong bleeding time in the mother and child, anticoagulant effects may occur even at low doses, and uterine contractions may be inhibited, prolonging or delaying delivery time. Therefore, aspirin should not be administered in the third trimester of pregnancy.
2) In an experiment in which it was administered to rats in the late stages of pregnancy, constriction of the ductus arteriosus in the fetus was reported.
3) This drug is not administered to lactating women because it transfers to breast milk.

8. Administration to elderly people
Since adverse reactions are more likely to occur in elderly people, administer carefully while observing the patient's condition, such as starting with a small amount.

9. Precautions for application (limited to enteric-coated preparations)
1) Be careful not to damage the enteric coating.
2) Do not mix with alkaline agents such as sodium bicarbonate and magnesium carbonate.
3) If possible, avoid mixing with agents that are easily wetted.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.

5. How to save
Airtight container, stored at room temperature (15~25℃)

6. Packaging unit
30 tablets/bottle, 300 tablets/bottle

7. Expiration date
36 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3KyungDong Aspirin enteric coated Tab.Precautions for use2025.04.15PDFKyungdong Aspirin Enteric Tablet_201309112_Precautions for use.pdf
2KyungDong Aspirin enteric coated Tab.Kyungdong aspirin enteric tablets (precautions for use)2021.02.09PDFPermission change order (draft)_Aspirin single drug (oral drug)_2021.02.09.pdf
1KyungDong Aspirin enteric coated Tab.Kyungdong aspirin enteric tablets (efficacy/effectiveness, usage/use...2017.06.01HWPUnification plan for aspirin single-pack enteric-coated tablets and enteric-coated capsules